Bone-Marrow-Derived Macrophages Genetically Modified to Produce IL-10 Reduce Injury in Experimental Glomerulonephritis
Open Access
- 1 December 2002
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 6 (6) , 710-717
- https://doi.org/10.1006/mthe.2002.0802
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Viral IL-10 Gene Transfer Inhibits DTH Responses to Soluble Antigens: Evidence for Involvement of Genetically Modified Dendritic Cells and MacrophagesMolecular Therapy, 2001
- Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritisJournal of Clinical Investigation, 2001
- Interleukin-10 and the Interleukin-10 ReceptorAnnual Review of Immunology, 2001
- Endogenous interleukin-10 regulates Th1 responses that induce crescentic glomerulonephritisKidney International, 2000
- Anti-Adenovirus Immune Responses in Rats Are Enhanced by Interleukin 4 but Not Interleukin 10 Produced by Recombinant AdenovirusHuman Gene Therapy, 1998
- ADENOVIRUS-MEDIATED GENE TRANSFER IN RAT LIVER OF INTERLEUKIN 4 BUT NOT INTERLEUKIN 10 PRODUCES SEVERE ACUTE HEPATITISCytokine, 1997
- Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes.Journal of Clinical Investigation, 1996
- IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity.The Journal of Experimental Medicine, 1996
- Interleukin‐10 inhibition of the progression of established collagen‐induced arthritisArthritis & Rheumatism, 1996
- High level of interleukin‐10 production by the activated t cell population within the rheumatoid synovial membraneArthritis & Rheumatism, 1995